AU2013241752B2 - Pharmaceutical diagnostic - Google Patents

Pharmaceutical diagnostic Download PDF

Info

Publication number
AU2013241752B2
AU2013241752B2 AU2013241752A AU2013241752A AU2013241752B2 AU 2013241752 B2 AU2013241752 B2 AU 2013241752B2 AU 2013241752 A AU2013241752 A AU 2013241752A AU 2013241752 A AU2013241752 A AU 2013241752A AU 2013241752 B2 AU2013241752 B2 AU 2013241752B2
Authority
AU
Australia
Prior art keywords
subject
amide
pi3k
subunit
catalytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013241752A
Other languages
English (en)
Other versions
AU2013241752A1 (en
Inventor
Christine Fritsch
Pascal Furet
Sauveur-Michel Maira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48083130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013241752(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013241752A1 publication Critical patent/AU2013241752A1/en
Application granted granted Critical
Publication of AU2013241752B2 publication Critical patent/AU2013241752B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013241752A 2012-03-29 2013-03-27 Pharmaceutical diagnostic Ceased AU2013241752B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261617284P 2012-03-29 2012-03-29
US61/617,284 2012-03-29
US201361767848P 2013-02-22 2013-02-22
US61/767,848 2013-02-22
PCT/EP2013/056600 WO2013144249A1 (en) 2012-03-29 2013-03-27 Pharmaceutical diagnostic

Publications (2)

Publication Number Publication Date
AU2013241752A1 AU2013241752A1 (en) 2014-09-25
AU2013241752B2 true AU2013241752B2 (en) 2016-07-07

Family

ID=48083130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013241752A Ceased AU2013241752B2 (en) 2012-03-29 2013-03-27 Pharmaceutical diagnostic

Country Status (25)

Country Link
US (1) US9795596B2 (enExample)
EP (1) EP2830621B1 (enExample)
JP (1) JP6224067B2 (enExample)
KR (1) KR20140138771A (enExample)
CN (1) CN104271136A (enExample)
AR (1) AR090544A1 (enExample)
AU (1) AU2013241752B2 (enExample)
BR (1) BR112014023530A2 (enExample)
CA (1) CA2866127A1 (enExample)
CL (1) CL2014002576A1 (enExample)
CO (1) CO7091176A2 (enExample)
EA (1) EA028984B1 (enExample)
EC (1) ECSP14025016A (enExample)
ES (1) ES2845560T3 (enExample)
GT (1) GT201400206A (enExample)
HK (1) HK1200723A1 (enExample)
IL (1) IL234658B (enExample)
IN (1) IN2014DN08970A (enExample)
MX (1) MX2014011682A (enExample)
NZ (1) NZ628596A (enExample)
PH (1) PH12014502168A1 (enExample)
SG (2) SG10201608001RA (enExample)
TW (1) TW201345525A (enExample)
WO (1) WO2013144249A1 (enExample)
ZA (1) ZA201405938B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014229240B2 (en) * 2013-03-15 2017-06-15 Novartis Ag Biomarkers of tumor pharmacodynamic response
EP3140427B1 (en) * 2014-05-09 2020-10-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors
KR102486126B1 (ko) * 2014-10-03 2023-01-09 노파르티스 아게 알펠리십을 포함하는 제약 조성물
US20180353515A1 (en) * 2015-12-03 2018-12-13 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna
WO2019199860A1 (en) * 2018-04-09 2019-10-17 The Research Foundation For The State University Of New York Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377933A1 (en) * 2008-12-23 2011-10-19 Guangzhou Surexam Bio-Tech Co., Ltd. Probes, liquid phase chips and methods for detecting pik3ca gene mutations
WO2012016970A1 (en) * 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2307414A4 (en) 2008-07-07 2011-10-26 Xcovery Holding Co Llc SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377933A1 (en) * 2008-12-23 2011-10-19 Guangzhou Surexam Bio-Tech Co., Ltd. Probes, liquid phase chips and methods for detecting pik3ca gene mutations
WO2012016970A1 (en) * 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor

Also Published As

Publication number Publication date
SG10201608001RA (en) 2016-11-29
US20150111927A1 (en) 2015-04-23
ES2845560T3 (es) 2021-07-27
AR090544A1 (es) 2014-11-19
ZA201405938B (en) 2015-11-25
BR112014023530A2 (pt) 2017-07-18
CN104271136A (zh) 2015-01-07
AU2013241752A1 (en) 2014-09-25
EP2830621B1 (en) 2020-10-21
EA028984B1 (ru) 2018-01-31
IL234658B (en) 2018-02-28
IN2014DN08970A (enExample) 2015-05-22
CL2014002576A1 (es) 2015-01-23
US9795596B2 (en) 2017-10-24
GT201400206A (es) 2017-09-28
HK1200723A1 (en) 2015-08-14
EA201491787A1 (ru) 2015-01-30
KR20140138771A (ko) 2014-12-04
PH12014502168A1 (en) 2014-12-10
JP6224067B2 (ja) 2017-11-01
CO7091176A2 (es) 2014-10-21
TW201345525A (zh) 2013-11-16
JP2015514080A (ja) 2015-05-18
WO2013144249A1 (en) 2013-10-03
NZ628596A (en) 2015-10-30
CA2866127A1 (en) 2013-10-03
SG11201405169SA (en) 2014-10-30
MX2014011682A (es) 2015-01-22
ECSP14025016A (es) 2015-09-30
EP2830621A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
JP6107812B2 (ja) 新規ｆｇｆｒ３融合体
EP3140427B1 (en) Biomarkers for response to pi3k inhibitors
AU2013241752B2 (en) Pharmaceutical diagnostic
US20090226459A1 (en) Role of fgf-19 in cancer diagnosis and treatment
TWI518325B (zh) 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
CN105658814A (zh) 在肺癌中检测出的新型融合基因
WO2015012397A1 (ja) Ｎｔｒｋ３融合体の検出法
JP2002345489A (ja) 化学物質
US20100204125A1 (en) Genetic alterations associated with cancer
GB2488028A (en) mTOR mutants as biomarkers for mTOR inhibitor treatment
WO2016116935A1 (en) Use of rasa2 as a prognostic and therapeutic marker for melanoma
Ruggeri et al. Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations
JP6731254B2 (ja) 新規融合体及びその検出法
ES2873049T3 (es) Método, secuencias, composiciones y kit para la detección de mutaciones en el promotor del gen Htert
US10551384B2 (en) MTOR kinase mutations and methods of use thereof
UA114808C2 (uk) Фармацевтична діагностика
Weeda Clinical and molecular insights into primary pediatric liver cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired